Finally, there was a high and positive correlation between days of survival and the CD8:Treg ratio at endterm (Fig. 3j), suggesting that HIF-2α inhibition mitigated glioma immunosuppression beyond TAMs, specifically impacting the Tregs. The gene discussed is CD8A; the disease is central nervous system cancer.